Press Release – New York, NY – August 20, 2025 – Sichenzia Ross Ference Carmel LLP announced that it represented D. Boral Capital LLC and Craft Capital Management LLC as the bookrunning managers for the recently priced $4 million underwritten public offering of Propanc Biopharma, Inc., a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer. The company also received approval to list its common stock on the Nasdaq Capital Market stock exchange, under the ticker symbol “PPCB.” The company’s shares of common stock were previously quoted on the OTC Markets, Pink Tier.
The D. Boral Capital team was led by David Boral, Gaurav Verma, John Park and Mark Iorio.
The Craft Capital Management team was led by Stephen Kiront.
The SRFC team was led by partner Ross Carmel, with associate Rohini Sud.